After Profitable Year, Genomic Health to Invest in New Products, Overseas Market, Next-Gen Sequencing

As the company looks to 2011 and beyond, it plans to continue to invest in growing its test menu, expanding its business overseas, and advancing sequencing efforts to ultimately develop the next generation of Oncotype DX tests.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.